# Sildenafil Administration to Treat Neonatal Encephalopathy

> **NCT02812433** · PHASE1 · COMPLETED · sponsor: **McGill University Health Centre/Research Institute of the McGill University Health Centre** · enrollment: 28 (actual)

## Conditions studied

- Neonatal Encephalopathy

## Interventions

- **DRUG:** Sildenafil
- **DRUG:** Ora-Blend

## Key facts

- **NCT ID:** NCT02812433
- **Lead sponsor:** McGill University Health Centre/Research Institute of the McGill University Health Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2019-01
- **Final completion:** 2022-01
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2022-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02812433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02812433, "Sildenafil Administration to Treat Neonatal Encephalopathy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02812433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*